Microbot Medical Announces Receiving a Notification of Granting a Patent Right for its ViRob Technology Platform in China

Microbot Medical (Nasdaq CM:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that the State Intellectual Property Office of China has issued a Notification of Granting a Patent Right for Chinese Patent Application No. 201410432156.7, which covers the Company’s ViRob™ technology platform.

As quoted in the press release:

“This is another significant milestone to protect and differentiate Microbot’s unique IP assets, especially as it relates to our technology platform, such as  ViRob™, from which we anticipate to deliver multiple novel products, including our SCS,” commented Harel Gadot, CEO, President and Chairman.  “We have worked to expand our patent estate and we anticipate additional patent allowances in the coming weeks as we seek to protect our ViRob™ and TipCAT™ technology platforms.  Coupled with the recent news about the successful conclusion of the pre-clinical study assessing the Company’s Self-Cleaning Shunt performed at Wayne State University by Dr. Carolyn Harris, we are continuing to execute against our goals which allow us to get closer to delivering our solutions to the market, protecting them and increasing shareholder value.”

The application covers an autonomous vibration-driven device for motion through a lumen. The device includes a body and an array of flexible fibers attached thereto, with at least some of the fibers maintaining contact with the inner wall of the lumen and having anisotropic surface friction therewith, such that mutual vibratory motion between the device and the inner wall of the lumen causes the device to move along the lumen.

Click here to read the full press release.